M&A deals of biopharma companies by deal value and upfront payment 2020
In 2020, Gilead acquired Immunomedics for 21 billion U.S. dollars, making the deal the largest biopharma acquisition deal of the year. Upfront cash and equity equaled the total value. This statistic illustrates the mergers and acquisitions of biopharmaceutical companies worldwide in 2020, by deal value and upfront cash and equity.
